<DOC>
	<DOCNO>NCT00839527</DOCNO>
	<brief_summary>The purpose study determine safety efficacy albiglutide subject type 2 diabetes</brief_summary>
	<brief_title>A Study Determine Safety Efficacy Albiglutide Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>type 2 diabetes BMI 2045kg/m2 inclusive female pregnant , lactate , less 6 week postpartum current symptomatic heart failure ( NYHA Class IIIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>diabetes</keyword>
</DOC>